NEW YORK, NY--(Marketwired - Dec 5, 2013) - Eli Lilly & Co. (LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced, inoperable pancreatic cancer back in 1996. Meanwhile, Nuvilex, Inc. (OTCQB: NVLX) has its eyes on a piece of that billion dollar pie with the company's live-cell encapsulation based treatment for pancreatic cancer. But, it may be another disease that has these two biotech's going head to head for years to come -- diabetes.

Nuvilex recently entered the diabetes arena when it acquired the exclusive worldwide licenses associated with live-cell encapsulation-based diabetes treatments. In a recent interview with Bloomberg, Eli Lilly's president of Lilly Diabetes, Enrique Conterno, said the company is preparing to introduce as many as four new therapies by 2016.

Nuvilex and Eli Lilly aren't strangers as both are engaged in treatments for advanced, inoperable pancreatic cancer and both have treatments in mind for the rapidly growing diabetes epidemic. This past summer Nuvilex acquired the exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment the company will be using in its future Phase III clinical trials. Now, with this most recent acquisition of the same exclusive worldwide rights, but this time associated with diabetes, Nuvilex controls both the cancer and diabetes markets when it comes to any treatment using this live-cell encapsulation-based technology.

Nuvilex will assuredly look to get its diabetes treatment into human clinical trials in the future after animal studies using the live-cell encapsulation-based technology, created a type of "artificial pancreas." An "artificial pancreas" was developed that controls blood sugar levels and eliminates the need for insulin treatment.

This data comes from a 6-month animal study where pancreatic islet cells from pigs were encapsulated using Nuvilex's technology and the capsules containing the islet cells were then implanted into diabetic rats. Within only a short time, the blood sugar levels of the rats became normal and stayed at normal levels for the duration of the study.

Continue Reading this Article:

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, Interviews and Feature Articles. For more information and to read disclaimers and disclosures:

Contact Information:

Stock Market Media Group